Clinical Trials – Essential Thrombocythemia & Polycythemia Vera (ET,PV)

Drug NameCompany or SponsorJAK2 InhibitorClinical Trial (click ID# for link to trial information) PhaseSite Locations / More Info
Ruxolitinib A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Incyte CorpNCT03123588 open, recruiting2Click here for more info
Anagrelide and Hydroxyurea for PVIncyte Corp.NoNCT02252159
open, not recruiting
Observational Studyclick here for trial info
DurvalumabCelgene
Celgene
The Leukemia and Lymphoma Society
National Cancer Institute (NCI)
NCT028713231Click here for trial info
MirabegronSwiss Group for Clinical Cancer ResearchNCT02311569
open, not recruiting
2click here for trial info
NS-018NS PharmaNoNCT01423851
open, not recruiting
2click here for trial info
P1101
Pegylated-Proline-interferon alpha-2b
PharmaEssentia
AOP Orphan Pharmaceuticals
NCT02218047
open, not recruiting
3Click here for more information
PegasysMDRC
NCI
Roche Pharma AG
Qiagen Marseille
NoNCT01259817
open, recruiting
2click here for trial info
Pegasys and HydroxyureaMDRC
NCI
Roche Pharma AG
Qiagen Marseille
YesNCT01259856
open, recruiting
3click here for trial info
RG7388
Pegasys
Genentech, Inc.
Roche Pharma AG
NCT024070801click here for trial info
RuxolitinibIncyte CorpNCT01348490
open, recruiting
2click here for trial info
RuxolitinibIncyte Corp
Novartis
YesNCT01317875
open, recruiting
1click here for trial info
RuxolitinibNovartisNCT02386800
open, recruiting
4-roll over protocolclick here for trial info
Ruxolitinib and DecitabineMPD-RCYesNCT02076191
open, recruiting
1
2
click here for trial info
SPD422Shire Pharmaceutical DevelopmentNoEffect of SPD422 on Platelet Lowering and Safety in Japanese Adults with At Risk Essential ThrombocythemiaJapan866-842-5335
XagridShire Pharmaceutical DevelopmentNoSafety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to Xagrid Compared to Other TreatmentsLondon, U.K.866-842-5335
Ruxolitinib
NovartisNCT02577926
open, recruiting
3click here for trial info
Momelotinib
Gilead SciencesNCT021012683click here for trial info
PacritinibCTI BioPharmaYesNCT02055781
active, not recruiting
withdrawn
3click here for trial info
PRM-151PromediorNCT01981850
open, recruiting
2Click here for location and trial info